Immunovant, Inc.
IMVT
Rangering i aksjer
#3098
Immunovant, Inc. is a biopharmaceutical firm in the clinical development phase,... Immunovant, Inc. is a biopharmaceutical firm in the clinical development phase, dedicated to advancing novel monoclonal antibody therapies for the treatment of various autoimmune conditions. The company's primary focus is batoclimab, a pioneering, fully human monoclonal antibody. This antibody is engineered to specifically target and block the neonatal fragment crystallizable receptor (FcRn), a key mechanism in certain autoimmune diseases. Batoclimab is currently undergoing Phase IIa clinical evaluations for treating both myasthenia gravis and thyroid eye disease. Additionally, it has commenced Phase II clinical studies for patients suffering from warm autoimmune hemolytic anemia. Established in 2018, Immunovant operates from its headquarters in New York, New York, functioning as a subsidiary under the umbrella of Roivant Sciences Ltd.
Aksjekurs
$28.32
Markedsverdi
$5.85B
Endring (1 dag)
-0.94%
Endring (1 år)
47.28%
Land
US
Handel Immunovant, Inc. (IMVT)
Kategori
Healthcare
Historikk for aksjesplitt for Immunovant, Inc. (IMVT)
Aksjen Immunovant, Inc. (symbol: IMVT) har gjennomgått totalt 0 aksjesplitt.
Den nyeste splittelsen skjedde Oct 21, 2026.
Én IMVT-aksje kjøpt før Oct 21, 2026 tilsvarer i dag 0 IMVT-aksjer.
Den nyeste splittelsen skjedde Oct 21, 2026.
Én IMVT-aksje kjøpt før Oct 21, 2026 tilsvarer i dag 0 IMVT-aksjer.
Liste over aksjesplitt
| År | Splitt | Multiplikator | Kumulativ multiplikator |
|---|---|---|---|
| Ikke nok data for de angitte datoene. | |||
Aksjesplitt for lignende selskaper eller konkurrenter
| Selskap | Antall aksjesplitt | Kumulativ multiplikator | Land |
|---|---|---|---|
| 1 | x2 |
US
|
|
| 0 | - |
US
|
|
| 1 | x3 |
AU
|
|
| 0 | - |
NL
|
|
| 0 | - |
CH
|
